Literature DB >> 2103360

Analysis of factors affecting human hybridoma production.

R A Watts1, H Winska-Wiloch, S Muller, D A Isenberg.   

Abstract

Human hybridomas were produced by fusion of the GM 4672 cell line with lymphocytes from the peripheral blood, spleen, and bone marrow of patients with systemic lupus erythematosus. Lymphocytes were also obtained from normal human fetal liver of 12 weeks' gestation. The influence of anatomical source, fusion ratio, pre-stimulation with pokeweed mitogen, HLA match, and disease activity at the time of fusion was studied. Supernatants were screened for immunoglobulin secretion and binding to DNA, cardiolipin, poly(ADP-ribose), and histones by enzyme-linked immunoassay. A total of 28 fusions from 14 donors and 6 fusions with fetal lymphocytes were performed. The spleen was found to be the most efficient source of lymphocytes, with a fusion ratio of 1:1 resulting in a maximum yield of 27 clones/10(7) lymphocytes fused. HLA matching was a factor influencing the outcome with HLA A2 matching being the most important. Pre-stimulation with pokeweed mitogen did not improve the fusion frequency, and fusions using lymphocytes from patients with active disease were only marginally more successful. Over 95% of clones secreted immunoglobulin; autoreactivity was found against DNA, histones, cardiolipin, and poly(ADP-ribose). All hybrids with autoreactivity secreted IgM.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2103360

Source DB:  PubMed          Journal:  Hum Antibodies Hybridomas        ISSN: 0956-960X


  2 in total

1.  The role of somatic mutation in determining the affinity of anti-DNA antibodies.

Authors:  M Behrendt; L J Partridge; B Griffiths; M Goodfield; M Snaith; N J Lindsey
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

2.  Production and analysis of IgG monoclonal anti-DNA antibodies from systemic lupus erythematosus (SLE) patients.

Authors:  M Ehrenstein; C Longhurst; D A Isenberg
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.